Provectus Biopharmaceuticals, Inc. (PVCT)
OTCMKTS · Delayed Price · Currency is USD
0.0476
-0.0058 (-10.82%)
At close: Mar 26, 2026

PVCT Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-5.51-4.76-3.1-3.55-5.54
Depreciation & Amortization
00.010.010.010.01
Stock-Based Compensation
1.241.28000.02
Other Operating Activities
0.050.050.050.050.02
Change in Accounts Receivable
-0-00-
Change in Accounts Payable
-0.39-0.57-0.420.810.33
Change in Unearned Revenue
-0.34-0.62-0.56-0.992.5
Change in Other Net Operating Assets
1.621.331.450.621.64
Operating Cash Flow
-3.33-3.28-2.57-3.04-1.01
Short-Term Debt Issued
---1.633.16
Long-Term Debt Issued
2.512.852.48--
Total Debt Issued
2.512.852.481.633.16
Short-Term Debt Repaid
-0.27-0.31-0.28-0.26-0.25
Long-Term Debt Repaid
--0.1---
Total Debt Repaid
-0.27-0.41-0.28-0.26-0.25
Net Debt Issued (Repaid)
2.242.452.191.372.91
Issuance of Common Stock
----0.96
Other Financing Activities
0.850.3--0.15
Financing Cash Flow
3.092.752.191.374.02
Foreign Exchange Rate Adjustments
0-0-0.02-0-0
Net Cash Flow
-0.24-0.54-0.4-1.683.01
Free Cash Flow
-3.33-3.28-2.57-3.04-1.01
Free Cash Flow Margin
-989.56%-532.15%-461.17%-307.52%-
Free Cash Flow Per Share
-0.01-0.01-0.01-0.01-0.00
Cash Interest Paid
0----
Levered Free Cash Flow
-2.86-2.93-1.16-0.88-6.94
Unlevered Free Cash Flow
-2.72-2.78-1.03-0.77-6.34
Change in Working Capital
0.890.140.470.454.47
Source: S&P Global Market Intelligence. Standard template. Financial Sources.